| Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02713386) | NRG Oncology | 2016-11-14 |
| Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer (NCT03902379) | Rutgers, The State University of New Jersey | 2016-07-27 |
| Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) (NCT02726997) | M.D. Anderson Cancer Center | 2016-07-06 |
| Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT02520154) | M.D. Anderson Cancer Center | 2016-07-05 |
| Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02316834) | M.D. Anderson Cancer Center | 2015-06-02 |
| Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02042430) | National Cancer Institute (NCI) | 2014-08-25 |
| TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (NCT02142803) | National Cancer Institute (NCI) | 2014-05-20 |
| Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer (NCT01970722) | City of Hope Medical Center | 2014-05-19 |
| Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00719303) | Gynecologic Oncology Group | 2012-06-18 |
| Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT01504126) | M.D. Anderson Cancer Center | 2012-03-09 |
| Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer (NCT01366183) | Gynecologic Oncology Group | 2011-08-15 |
| Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer (NCT01372787) | Gynecologic Oncology Group | 2011-04-12 |
| Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (NCT01167712) | National Cancer Institute (NCI) | 2010-09-27 |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00989651) | National Cancer Institute (NCI) | 2009-10-28 |
| Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer (NCT00954174) | GOG Foundation | 2009-08-17 |
| Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer (NCT00108745) | GOG Foundation | 2005-03-21 |